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Hepatitis C virus (HCV) is an important human pathogen associated with chronic liver disease. Recently,
based on a genotype 2a isolate, tissue culture systems supporting complete replication and infectious virus
production have been developed. In this study, we used cell culture-produced infectious HCV to analyze the
viral entry pathway into Huh-7.5 cells. Bafilomycin A1 and concanamycin A, inhibitors of vacuolar ATPases,
prevented HCV entry when they were present prior to infection and had minimal effect on downstream
replication events. HCV entry therefore appears to be pH dependent, requiring an acidified intracellular
compartment. For many other enveloped viruses, acidic pH triggers an irreversible conformational change,
which promotes virion-endosomal membrane fusion. Such viruses are often inactivated by low pH. In the case
of HCV, exposure of virions to acidic pH followed by return to neutral pH did not affect their infectivity. This
parallels the observation made for the related pestivirus bovine viral diarrhea virus. Low pH could activate the
entry of cell surface-bound HCV but only after prolonged incubation at 37°C. This suggests that there are
rate-limiting, postbinding events that are needed to render HCV competent for low-pH-triggered entry. Such
events may involve interaction with a cellular coreceptor or other factors but do not require cathepsins B and
L, late endosomal proteases that activate Ebola virus and reovirus for entry.
Hepatitis C virus (HCV) is the sole member of the Hepaci-
virus genus within the family Flaviviridae. HCV can cause a
persistent infection in humans that is associated with chronic
liver disease and hepatocellular carcinoma (27). Flaviviridae
are enveloped viruses with a single-stranded RNA genome of
positive polarity (reviewed in reference 24). Within the virion,
HCV genomic RNA is complexed with multiple copies of cap-
sid protein (C). The viral envelope bears on its surface two type
I integral membrane envelope glycoproteins, E1 and E2, which
form heterodimers (30). Both E1 and E2 have been shown to
accumulate in the endoplasmic reticulum, where particles are
thought to assemble (30).
Infection with an enveloped virus requires a fusion event
between the viral membrane and a cellular membrane. This
event can occur at the cell surface, as demonstrated by human
immunodeficiency virus (HIV) and herpes simplex virus
(HSV), where binding to one or more receptors induces con-
formational changes in the envelope glycoprotein, allowing
membrane fusion at neutral pH. Alternatively, the fusion event
can occur within an endosomal compartment in the presence
of low pH (reviewed in reference 39), as has been previously
described for classical flaviviruses and pestiviruses as well as
alphaviruses (8, 12, 14, 15, 20).
Previous studies of HCV entry have been based on retroviral
pseudotypes bearing HCV E1 and E2 glycoproteins (HCVpp)
(3, 17). Such pseudotypes were shown to undergo pH-depen-
dent entry into Huh-7 cells in a CD81-dependent manner and
could be neutralized by certain anti-E2 monoclonal antibodies
(17, 49). Additional receptors, including low-density lipopro-
tein receptor and scavenger receptor BI, have also been sug-
gested to have a role in HCV entry (1, 4, 22, 36, 44).
By using the JFH genotype 2a strain of HCV, it has recently
become possible to propagate infectious HCV particles in cell
culture (HCVcc), allowing the study of the complete viral life
cycle (23, 45, 50), including virus entry and fusion events. In
this report, we demonstrate that HCVcc entry into Huh-7.5
cells is pH dependent although HCV virions are acid resistant,
suggesting that HCV may have a mechanism of entry similar to
that of the pestivirus bovine viral diarrhea virus (BVDV). The
trigger(s) by which an acid-resistant virus becomes pH sensitive
during entry was investigated. This work provides the first
description of the mechanism of HCV entry into tissue culture
cells.
MATERIALS AND METHODS
Cells, virus stocks, and chemicals. Huh-7.5 cells were maintained in Dulbec-
co’s modified Eagle’s medium supplemented with 10% heat-inactivated fetal
bovine serum and 1 nonessential amino acids. Media and reagents were pur-
chased from GIBCO-BRL, Life Technologies Ltd. Stocks of J6/JFH and FL-J6/
JFH-5C19Rluc2AUbi were generated by transfection of in vitro-transcribed
RNA into Huh-7.5 cells. Stocks of Toto1101/Luc (5), a Sindbis virus (SIN)
expressing firefly luciferase, were generated by electroporation of in vitro-tran-
scribed RNA into BHK-J cells (25). Stocks of KOS/Dlux/oriL (41), HSV-1
expressing firefly luciferase, were generated by infection of Vero cells at a
multiplicity of infection (MOI) of 0.01 and harvesting of cell supernatants.
Bafilomycin A1, concanamycin A, and CA-074 were purchased from Sigma (St.
Louis, Mo.). FYdmk [Z-Phe-Tyr-(tBu)-diazomethylketone] was purchased from
Calbiochem (San Diego, Calif.).
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Construction of FL-J6/JFH-5C19Rluc2AUbi. FL-J6/JFH-5C19Rluc2AUbi is
a monocistronic, full-length HCV genome that expresses Renilla luciferase
(Rluc) and was derived from the previously described infectious genotype 2a
HCV genome J6/JFH1 (23). For the construction of FL-J6/JFH-
5C19Rluc2AUbi, an MluI site was introduced into the HCV C protein coding
sequence of J6/JFH and was used to fuse Rluc, the gene encoding Renilla
luciferase, to the first 19 residues of HCV C protein. Rluc was amplified from
pRL-CMV (Promega) by PCR using primers that incorporated MluI and BglII
sites. To allow removal of Rluc from the HCV polyprotein, a 17-residue frag-
ment of the self-cleaving foot-and-mouth disease virus 2A protein (2A) and the
ubiquitin monomer (Ubi) were fused to the C terminus of Rluc as follows. A
DNA cassette encoding 2A protein and Ubi in tandem (2AUbi) was amplified
from 213_HCVrep GFP-2A-Ubi-Neo (A. Kolykhalov and C. M. Rice, unpub-
lished data) by PCR. 2AUbi was fused to the C terminus of Rluc using an
engineered BglII site while the C terminus of Ubi was fused to the start of the
HCV polyprotein using overlapping PCR.
RNA transcription. FL-J6/JFH-5C19Rluc2AUbi RNA for electroporation
was generated essentially as described in reference 23 by in vitro transcription of
XbaI-linearized DNA templates using the T7 MEGAscript kit (Ambion), fol-
lowed by purification using the RNeasy Mini kit (QIAGEN) with on-column
DNase treatment.
Electroporation and generation of FL-J6/JFH-5C19Rluc2AUbi virus stocks.
Subconfluent Huh-7.5 cells were trypsinized, harvested by centrifugation (500 
g for 5 min), washed twice, and resuspended in ice-cold phosphate-buffered
saline (PBS; Accugene) at 1.5  107 cells/ml. FL-J6/JFH-5C19Rluc2AUbi RNA
(2 g) was mixed with 0.4 ml of cells in a 0.2-cm gap cuvette and immediately
pulsed using a BTX ElectroSquarePorator essentially as described previously
(23). Electroporated cells were allowed to recover for 10 min at room temper-
ature prior to the addition of complete medium and were then plated in a
150-mm diameter cell culture dish. After 72 h, electroporated cells were
trypsinized and replated in complete medium. Virus stocks containing superna-
tant from replated cells were then harvested after an additional 3 to 4 days of
incubation. Virus stocks were stored at 80°C until use.
Luciferase assay. To harvest samples for luciferase assays, cells were washed
once with Dulbecco’s PBS (DPBS), and then 100 l of Renilla lysis buffer (HCV
samples) (Promega) or passive lysis buffer (SIN or HSV-1 samples) (Promega)
was added to each well of a 24-well plate. Lysates were harvested and frozen at
80°C. Frozen samples were thawed and vortexed, and 50 l of sample was
mixed with luciferase assay substrate (Promega). Luciferase activity was typically
measured for 10 seconds, using a luminometer.
Growth kinetics of FL-J6/JFH-5C19Rluc2AUbi. Huh-7.5 cells, seeded in a
24-well plate, were chilled on ice for 5 min and incubated with 200 l FL-J6/
JFH-5C19Rluc2AUbi (MOI, 0.01) for 2 h at 4°C. After incubation, the cells
were washed twice with cold DPBS, and warm medium was added. Cells were
incubated at 37°C for the appropriate time until being harvested for luciferase
assays.
Chemical inhibitor experiments. Huh-7.5 cells (typically 5  104/well) were
seeded in a 24-well plate. Cells were pretreated with drug (bafilomycin A1,
concanamycin A, or NH4Cl) for 1 h at 37°C. The cells were then chilled on ice
for 5 min and infected with HCV (FL-J6/JFH-5C19Rluc2AUbi), SIN (To-
to1101/Luc), or HSV-1 (KOS/Dlux/oriL) for 2 h at 4°C. Once added to a par-
ticular well, the drug was present for the duration of the experiment. After
binding, the cells were washed twice with cold DPBS, and then warm medium
with or without drug was added. For postinfection drug addition, the drug was
added directly to the medium in the well. SIN and HSV-1 samples were har-
vested at 12 hours postinfection (h p.i.). HCV samples were harvested at 24 h p.i.
Low-pH treatment. HCV or SIN stocks, in medium containing 20 mM
HEPES, were diluted 1:5 in a citric acid buffer (15 mM citric acid, 150 mM NaCl)
at either pH 4.10 or 7.00. The final pHs of the solutions were pH 5 and 7,
respectively. For experiments with reducing agent, 10 mM dithiothreitol (DTT)
was included in the citric acid buffer. The buffers containing the diluted virus
were incubated in a 37°C water bath for 10 min. After incubation, to neutralize
the pH, a one-tenth volume of Dulbecco’s modified Eagle’s medium containing
150 mM HEPES was added. Each sample was then diluted 1:10 in medium
containing 20 mM HEPES.
HCV and SIN entry at the plasma membrane. Huh-7.5 cells were treated with
bafilomycin A1 (25 nM) for 1 h at 37°C and then infected with HCV or SIN in
the presence of bafilomycin for 2 h at 4°C. After 2 h, cells were sequentially
washed with cold DPBS, warm citric acid buffer (pH 7 or 5), and medium.
Medium containing bafilomycin was replaced, and cells were incubated at 37°C.
Samples were harvested at 24 h p.i. For experiments with reducing agent, 10 mM
DTT was included in the citric acid buffer. For HCV-infected cells that were
shifted to 37°C prior to the low-pH wash, after 1 h at 37°C, cells were removed
from the incubator and washed as indicated above with DPBS, citric acid buffer
(pH 7 or 5), and medium. Medium containing bafilomycin was replaced, and cells
were incubated at 37°C. Samples were harvested at 24 h p.i.
Cathepsin B/L inhibitor experiments. Huh-7.5 cells, seeded in a 24-well plate,
were pretreated with CA-074 (100 M) or FYdmk (0.1 M) for 3.5 h at 37°C.
Cells were infected for 2 h at 37°C with HCV, HIV expressing firefly luciferase
pseudotyped with vesicular stomatitis virus envelope glycoprotein (VSV-G)
(HIV-VSV-G), or VSV expressing green fluorescent protein pseudotyped with
Ebola virus glycoprotein (VSV-EboV GP) (7) (a generous gift from James
Cunningham). Cells were washed and incubated for 24 h at 37°C. Drug was
present in treated wells for the duration of the experiment. At 24 h p.i., cells were
harvested for luciferase assays (HCV, HIV-VSV-G) or flow cytometry (VSV-
EboV GP). Flow cytometry was performed on a FACSCalibur (Becton Dickin-
son), counting 104 cells.
RESULTS
HCV entry is pH dependent. To examine the HCV entry
pathway into Huh-7.5 cells, we utilized an HCV reporter virus
termed FL-J6/JFH-5C19Rluc2AUbi (Fig. 1A), which was de-
rived from the previously reported infectious genotype 2a J6/
JFH chimeric virus (23). FL-J6/JFH-5C19Rluc2AUbi encodes
the first 19 residues of the HCV C protein fused to the N
terminus of Renilla luciferase. The C terminus of Rluc is fused
to a 17-residue fragment from the self-cleaving foot-and-
mouth disease virus 2A protein, a Ubi sequence, and finally the
complete HCV polyprotein. Together, 2A and Ubi mediate
removal of Rluc from the HCV polyprotein and generate the
native N terminus of the HCV C protein. The expression of
Rluc from FL-J6/JFH-5C19Rluc2AUbi serves as highly sensi-
FIG. 1. Characterization of FL-J6/JFH-5C19Rluc2AUbi. (A) Sche-
matic of HCV and FL-J6/JFH-5C19Rluc2AUbi genomes. The 5 non-
translated region contains an internal ribosome entry site (IRES),
which allows translation of the HCV polyprotein (shaded boxes) con-
taining structural (C, E1, E2) and nonstructural proteins (p7, NS2,
NS4A, NS4B, NS5A, and NS5B). FL-J6/JFH-5C19Rluc2AUbi is a
full-length HCV genome encoding Rluc, a foot-and-mouth disease
virus 2A sequence, and a Ubi sequence. The N terminus of Rluc is
fused to the first 19 residues of the HCV C protein (see Materials and
Methods). (B) Huh-7.5 cells were infected with FL-J6/JFH-
5C19Rluc2AUbi for 0, 4, 6, 8, 10, 12, 20, 24, 30, 36, or 48 h. At each
time point, cells were harvested and luciferase activity was determined.
Each point is the average value of triplicate wells; error bars show
standard deviations. The dashed line indicates the background level of
the assay from naive Huh-7.5 cells. RLU, relative light units.
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tive assay for viral RNA replication after infection of permis-
sive cells. To examine the replication kinetics of FL-J6/JFH-
5C19Rluc2AUbi in Huh-7.5 cells, virus was bound to cells at
4°C, and then the cells were shifted to 37°C for a 48-h period
of infection. After a low-level infection (MOI, 0.01), a small
increase in signal was observed after 8 to 12 h, followed by a
logarithmic rise in the luciferase activity between 12 and 24 h
p.i. (Fig. 1B).
To determine whether HCV entry is dependent on a low-pH
step, we utilized bafilomycin A1, concanamycin A, and NH4Cl,
agents that prevent the acidification of endosomal compart-
ments. As controls for these experiments, we infected Huh-7.5
cells in parallel with SIN or HSV-1, which are well-character-
ized pH-dependent and -independent viruses, respectively.
SIN undergoes receptor-mediated endocytosis, followed by fu-
sion in the acidic environment of the endosome, while HSV-1
fuses at the plasma membrane at a neutral pH (39).
Huh-7.5 cells were pretreated with various concentrations of
bafilomycin A1, an inhibitor of vacuolar type H-ATPase, and
were then infected with HCV, SIN, or HSV-1. At all concen-
trations tested, a 3-h pretreatment with bafilomycin reduced
HCV-expressed luciferase activity to nearly background levels
(Fig. 2A) while having no effect on HSV-1 infection (Fig. 2B).
SIN infection was inhibited in a manner similar to that of HCV
by pretreatment of cells with bafilomycin (data not shown). To
confirm that the drug was acting at viral entry and not at
subsequent replication steps, bafilomycin was added at 3 h p.i.
with HCV, SIN, or HSV-1, with minimal effect on HCV or SIN
luciferase activity (Fig. 2A and data not shown). As expected,
HSV-1 was unaffected by the presence of bafilomycin at the 3-h
p.i. time point (Fig. 2B).
To determine the time point postinfection at which HCV
loses sensitivity to bafilomycin treatment, we performed a time
course of bafilomycin addition during HCV infection. Cells
were treated with bafilomycin prior to HCV infection (3 h),
at the time of infection at 4°C (2 h), after inoculum was
removed and cells were shifted to 37°C (0 h), or at 1, 2, 3, 4, 5,
or 6 h p.i. (Fig. 2C). Drug addition at 1 h p.i. or after had little
effect on HCV luciferase activity, but if bafilomycin was
present at 3, 2, or 0 h, the luciferase signal was nearly
eliminated (Fig. 2C). These data suggest that soon after the
temperature shift to 37°C, bound HCV virions are able to enter
Huh-7.5 cells, thereby becoming insensitive to bafilomycin
treatment.
To further confirm that HCV requires a pH-dependent en-
try step, we tested another inhibitor of vacuolar type H-
ATPase, concanamycin A. Concanamycin A inhibited HCV
and SIN entry into Huh-7.5 cells but had minimal effect on
downstream replication events (Fig. 3A and data not shown).
Pre- or postinfection treatment with concanamycin A had no
effect on HSV-1 infection (Fig. 3B). Infection in the presence
of NH4Cl, a lysosomotropic agent, was also tested for its ability
to inhibit HCV entry. Pretreatment with 25 mM NH4Cl inhib-
ited HCV (Fig. 3C), but similar inhibition was also observed
when the drug was added at 3 h p.i. (data not shown). This
observation was unlike that for SIN, which was inhibited in a
dose-dependent manner by pretreatment with NH4Cl, but the
inhibition was much decreased when the drug was present
from only 3 h p.i. (data not shown). HSV-1 infection was
unaffected by the presence of 25 mM NH4Cl, indicating that
the decrease in HCV luciferase activity for the 3-h posttreat-
ment was not likely due to nonspecific or cytotoxic effects of
NH4Cl on the Huh-7.5 cells (Fig. 3C). These data suggest that
HCV may require an additional low-pH step for downstream
replication events that is inhibited by NH4Cl. Taken together,
HCV sensitivity to bafilomycin A1, concanamycin A, and
NH4Cl demonstrates that HCV entry requires a low-pH step.
FIG. 2. HCV entry is sensitive to bafilomycin A1 (Baf). (A) Huh-
7.5 cells were incubated with bafilomycin A1 (0, 25, 50, or 100 nM)
either prior to infection (squares) or at 3 h p.i. (triangles) with HCV.
Samples were harvested for luciferase assays at 24 h p.i. Each point is
the average value of triplicate wells; error bars show standard devia-
tions. The dashed line indicates the background level of the assay from
naive Huh-7.5 cells. (B) Huh-7.5 cells were incubated with bafilomycin
A1 (0, 25, 50, or 100 nM) either prior to infection (squares) or at 3 h
p.i. (triangles) with HSV-1. Samples were harvested for luciferase
assays at 12 h p.i. Each point is the average value of triplicate wells;
error bars show standard deviations. (C) Huh-7.5 cells were untreated
or incubated with bafilomycin A1 prior to infection (3 h), at the time
of infection (2 h), or at 0, 1, 2, 3, 4, 5, or 6 h p.i. with HCV. Samples
were harvested for luciferase assays at 24 h p.i. Values are expressed as
percentages of untreated RLU and are the combined data from two
independent experiments done in triplicate; error bars represent stan-
dard errors of the means.
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HCV infectivity is unaffected by low-pH treatment. Envel-
oped viruses that are internalized by endocytosis are, in gen-
eral, very sensitive to low-pH treatment. Exposure to acidic pH
induces a conformational change in the envelope glycoproteins
that prematurely exposes the fusion peptide and thereby di-
minishes the viral infectivity. To determine whether HCV in-
fectivity is sensitive to acidic pH, we treated virions with pH 5
or 7 buffers. After neutralization, the virus was used to infect
Huh-7.5 cells. SIN was again used as a control, being a well-
characterized acid-sensitive virus that is readily inactivated by
low-pH treatment. Treatment at pH 5 for 10 min at 37°C had
minimal effect on HCV infectivity but reduced SIN luciferase
activity to less than 1% of the pH 7 value (Fig. 4A). These data
suggest that unlike SIN virions, which are primed to undergo
fusion upon exposure to low pH, HCV requires an additional
trigger to become acid sensitive. However, we cannot exclude
the possibility that low pH induces a conformational change
that is reversible upon neutralization, similar to what has been
observed for VSV and rabies virus (10, 11). The observed
insensitivity of HCV to low-pH treatment is reminiscent of the
related pestivirus BVDV (20).
HCV fails to enter bafilomycin-treated cells when exposed to
low pH. Many viruses that utilize the acidic environment of the
endosome to trigger glycoprotein-mediated fusion can be in-
duced to fuse at the plasma membrane with a brief low-pH
treatment. Whereas free virus is inactivated, cell-bound virus
can enter and initiate infection. Using SIN as a control, we
tested whether HCV bound at the plasma membrane could
FIG. 3. HCV entry is sensitive to concanamycin A (Con A) and
NH4Cl. (A) Huh-7.5 cells were incubated with concanamycin A (0,
12.5, 25, or 50 nM) prior to infection (squares) or at 3 h p.i. (triangles)
with HCV. Samples were harvested for luciferase assays at 24 h p.i.
The dashed line indicates the background level of the assay from naive
Huh-7.5 cells. (B) Huh-7.5 cells were incubated with concanamycin A
(0, 12.5, 25, or 50 nM) prior to infection (squares) or at 3 h p.i.
(triangles) with HSV-1. Samples were harvested for luciferase assays at
12 h p.i. (C) Huh-7.5 cells were untreated (0 nM) or incubated with 25
mM NH4Cl prior to infection with HCV (black bars) or HSV-1 (white
bars). Samples were harvested for luciferase assays at 24 h p.i. In
panels A, B, and C, each point or bar is the average value of triplicate
wells; error bars show standard deviations.
FIG. 4. HCV infectivity is resistant to acidic pH. (A) HCV or SIN
was diluted in citric acid buffer (15 mM citric acid, 150 mM NaCl) at
pH 7 (white bars) or pH 5 (black bars) for 10 min at 37°C. Samples
were then neutralized and used to infect Huh-7.5 cells. Samples were
harvested at 24 h (SIN) or 48 h (HCV) for luciferase assays. Values,
expressed as percentages of pH 7 RLU, are the combined data from
two independent experiments done in triplicate; error bars represent
standard errors of the means. (B) Huh-7.5 cells were treated with
bafilomycin A1 (Baf) (25 nM) and then were infected with HCV
(black bars) or SIN (white bars) at 4°C for 2 h. Cells were washed to
remove unbound virus and then washed with citric acid buffer at pH 7
or 5. Cells were incubated in the presence of bafilomycin A1 for 24 h
when they were harvested for luciferase assays. Luciferase activity from
untreated cells washed with the pH 7 buffer (Baf/pH 7) was ex-
pressed as 100 percent. Values are the combined data from two inde-
pendent experiments done in triplicate; error bars represent standard
errors of the means.
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enter when exposed to low pH. Huh-7.5 cells were pretreated
with bafilomycin to prevent productive entry via endosomal
acidification. Cells were then infected with HCV or SIN at 4°C.
After the cells were washed to remove unbound virus, they
were rinsed with prewarmed buffer at pH 5 or 7 and then
incubated in the presence of bafilomycin at 37°C. While there
was no increase in HCV luciferase activity from samples
washed with the pH 5 buffer, SIN luciferase activity increased
to nearly 50% of the untreated values in samples that had been
washed with the pH 5 buffer (Fig. 4B). Therefore, cell surface-
bound HCV is unable to enter at the plasma membrane under
the same conditions as those of SIN. These results suggest that
cell-bound HCV remains acid resistant and requires an addi-
tional trigger for low-pH-induced infection.
In the case of BVDV, the presence of reducing agent in
addition to low pH has been reported to allow some, albeit
inefficient, entry and replication (20). Therefore, we repro-
duced this experiment with HCV by including 10 mM DTT in
the pH 5 buffer. No enhancement of the luciferase signal was
observed (data not shown). However, this experiment is diffi-
cult to interpret since treatment of HCV with DTT, either at
pH 5 or pH 7, abrogated detectable HCV infection (data not
shown). It is unclear whether DTT is mediating this effect by
destabilizing the HCV glycoproteins or cell surface receptors
such as CD81, which contains a disulfide bond in its large
extracellular loop that is required for E2 binding (16, 32).
HCV entry is not dependent on cathepsin B or L. As de-
scribed above for HCV, EboV entry is sensitive to inhibitors of
endosomal acidification (42, 47), but acid pH cannot induce
glycoprotein-dependent membrane fusion (18). A recent study
demonstrated that infection with VSV virions pseudotyped
with EboV GP depends on the action of pH-dependent endo-
somal proteases cathepsin B (CatB) and cathepsin L (CatL)
(7). We therefore tested whether endosomal proteolysis by
CatB or CatL is required for HCV entry.
Huh-7.5 cells pretreated with CA-074, an inhibitor of CatB,
or with FYdmk, an inhibitor of both CatB and CatL, were
infected with either HCV, HIV-VSV-G as a negative control,
or VSV-EboV GP (7). Both HCV and HIV-VSV-G infections
were unaffected by CA-074 or FYdmk, although either inhib-
itor reduced the efficiency of VSV-EboV GP infection by ap-
proximately 80% compared to untreated cells (Fig. 5). This
experiment demonstrates that HCV infection is not sensitive to
inhibitors of CatB and CatL, suggesting that in contrast to
EboV, these endosomal proteases do not have a significant
role in HCV entry.
Evidence that additional postbinding steps are required to
activate HCV for entry. The inability of bound HCV to enter at
the plasma membrane after exposure to low pH (Fig. 4B)
suggested that an additional step(s) was required to activate
the virus for pH-dependent entry. For some viruses, such as
ALV (29), and Semliki Forest virus and VSV in certain cell
types (28), fusion in the presence of inhibited endosomal acid-
ification requires incubation at 37°C prior to acid treatment.
We examined whether low pH could override the bafilomycin
block to HCV infection if the cells were shifted to 37°C prior
to the pH 5 wash. After 1 h at 37°C, the HCV-infected cells
were washed with buffer at pH 5 or 7. In contrast to what we
observed when the cells were washed immediately with low pH
(Fig. 6, 0 h p.i.), luciferase activity from cells that had been
incubated at 37°C prior to the low-pH wash increased to ap-
proximately 15% of the untreated value (Fig. 6, 1 h p.i.). Again,
no increase in luciferase activity was observed from cells that had
been washed with the pH 7 buffer (Fig. 6, 1 h p.i.). These results
suggest that HCV requires an event that occurs within 1 h p.i.,
possibly at the cell surface or within a forming endosome, for low
pH to trigger entry in the presence of bafilomycin.
DISCUSSION
The sensitivity of HCV to agents that inhibit endosomal
acidification strongly suggests that HCV requires a low-pH
FIG. 5. HCV is unaffected by inhibitors of CatB and CatL. Huh-7.5
cells were pretreated with CA-074 (100 M), a CatB selective inhibi-
tor, or FYdmk (0.1 M), a CatB/CatL inhibitor, and were then in-
fected with HCV (black bars), HIV-VSV-G (gray bars), or VSV-EboV
GP (white bars) for 2 h at 37°C. Cells were incubated in the presence
of inhibitor for 24 h. At 24 h p.i., cells were harvested for luciferase
assays (HCV, HIV-VSV-G) or fluorescence-activated cell sorter anal-
ysis (VSV-EboV GP). The luciferase activity or number of green
fluorescent protein (GFP)-positive cells from untreated cells is ex-
pressed as 100 percent. Each bar is the average value of triplicate wells;
error bars show standard deviations.
FIG. 6. Incubation at 37°C allows HCV to enter bafilomycin-
treated cells. Huh-7.5 cells were treated with bafilomycin A1 (Baf)
(25 nM) and then infected with HCV at 4°C for 2 h. Cells were washed
to remove unbound virus and then washed with citric acid buffer at pH
7 (white bars) or 5 (black bars) immediately (0 h p.i.) or after 1 h at
37°C (1 h p.i.). Cells were incubated in the presence of bafilomycin A1
for 24 h when they were harvested for luciferase assays. Luciferase
activity from untreated cells washed with pH 7 buffer (Baf) was
expressed as 100 percent. Values are the combined data from two
independent experiments done in triplicate; error bars represent stan-
dard errors of the means.
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step to enter Huh-7.5 cells. The loss of sensitivity to bafilomy-
cin and concanamycin, within 3 h p.i., demonstrates that these
agents inhibit an early event in HCV infection and not down-
stream replication events. Such a pH-dependent route of entry
is a common feature among viruses of the Flaviviridae. The
observation that HCV virions are acid resistant is similar to
that of members of the Pestivirus genus. The inability of HCV
to infect a bafilomycin-treated cell after exposure to low pH
under the same conditions that could induce fusion of the
alphavirus SIN suggests that a postbinding maturation step is
required to render the virus competent for low-pH-triggered
entry.
The HCVpp system has provided clues to the mechanism of
HCV entry into cells, which can now be tested directly using
HCVcc. Many of the observations made with HCVpp, such as
receptor usage and pH-dependent entry, have now been con-
firmed in the HCVcc system. For example, the role of CD81 in
HCV infection, previously demonstrated using HCVpp (49), is
also important for entry of HCVcc (23, 45, 50). As we have
found for HCVcc entry, HCVpp entry is also pH dependent
and sensitive to concanamycin A and NH4Cl (17). Interest-
ingly, in contrast to the data presented here, Hsu et al. re-
ported that HCVpp (genotype 1a, strain H77) were moderately
susceptible to inactivation by low pH (17). The basis for this
difference is unknown but could reflect differences in the HCV
strains used in the two studies or the experimental systems
themselves. If the incorporation of HCV E1E2 heterodimers
into HCVpp is similar to that of gp120/gp41 into HIV particles
(48), then each HCVpp may harbor fewer than 10 copies of
functional HCV E1E2 heterodimers. In contrast, if HCVcc
particles resemble those of the classical flaviviruses, which con-
sist of 90 envelope protein dimers (21), the HCVcc surface
may consist of tightly packed glycoprotein oligomers. One
could imagine that such a lattice, stabilized by lateral interac-
tions, might be more acid resistant. Thus, while entry studies
using HCVpp and HCVcc have yielded remarkably convergent
results, some features may differ. It will be important to con-
tinue to compare these two systems and attempt to extend
entry studies to in vivo-produced viruses and other cell types,
including primary hepatocytes.
Low pH induces conformational changes to the envelope
glycoproteins of many viruses that enter cells by endocytosis,
allowing fusion between viral and cellular membranes. Two
classes of viral fusion proteins, class I and class II, that mediate
entry of enveloped viruses have been defined (13). Influenza
hemagglutinin (HA) is a prototype class I fusion protein (38).
HA is primed for activation during assembly of influenza viri-
ons by proteolytic cleavage, which liberates an N-terminal fu-
sion peptide. When exposed to low pH, HA undergoes a dra-
matic conformational change, which exposes the fusion
peptide promoting interaction with membranes for fusion.
Class II fusion proteins, found in alphaviruses and classical
flaviviruses, are distinct from class I fusion proteins in their
structure, mechanism of action, and apparent evolutionary or-
igin. Alphavirus and flavivirus glycoprotein precursors PE2 and
prM, respectively, serve dual roles in virus maturation. As
precursors, PE2 and prM act as chaperones to protect the viral
fusogens E1 and E from exposure to the low-pH environment
of the trans-Golgi network, which would otherwise trigger ex-
posure of the fusion peptide and premature fusion. During
virion maturation, PE2 and prM are cleaved by furin, releasing
their N-terminal fragments and rendering the viral fusogens
competent for pH-triggered fusion during entry (13, 14, 26).
These fusion proteins have a well-defined dimer-to-trimer
transition upon exposure to low pH (2, 19, 40). With the
exception of the G proteins of the rhabdoviruses, VSV (10)
and rabies virus (11), the transition of class I or class II pro-
teins to the fusogenic state is irreversible.
The observation that HCV infectivity is resistant to acidic
pH is surprising given its route of transmission through direct
blood-to-blood exposure. In contrast, pestiviruses have long
been known to be acid resistant, which fits with their need for
protection against low pH as they travel through the ruminant
digestive system. This shared characteristic of acid resistance
could be the result of a common evolutionary origin and may
have been retained by HCV. Alternatively, production of acid-
resistant virions may simply reflect a common strategy in the
HCV and pestivirus life cycles. As mentioned earlier, the prM
accessory protein of the classical flaviviruses provides protec-
tion during egress from the low-pH environment of the cellular
secretory pathway upon virion maturation; cleavage of this
protein prior to release renders the virus competent for acid-
catalyzed fusion and activates the virions for fusion. For HCV
and the pestiviruses, there is no evidence of such a proteolytic
maturation event during assembly or release (31, 33, 43), sug-
gesting that activation for subsequent low-pH-requiring steps
must occur during entry. Activation could theoretically occur
at any of the multiple steps involved in the viral entry pathway,
e.g., binding to a receptor at the cell surface, sequential binding
to a receptor and coreceptor, or assembly of multiple factors at
the cell surface, or within a forming or mature endosome.
In the case of BVDV, evidence exists for activation via
disulfide bond reshuffling. The three pestiviral glycoproteins
are stabilized by a combination of intra- and intermolecular
disulfide bonds. Treatment with DTT decreased BVDV’s re-
sistance to acidic pH and enhanced its ability to enter at the
plasma membrane in the presence of low pH (20). It has been
suggested that DTT might act by mimicking the action of
protein disulfide isomerases (PDIs) at the cell surface or within
the endocytic pathway that are required to destabilize the
BVDV glycoproteins and prime them for fusion upon exposure
to low pH. The role of PDIs in the entry of other viruses, such
as HIV and Moloney murine leukemia virus, has been dem-
onstrated (34, 35, 46). In our experiments, the possible contri-
bution of disulfide bond reshuffling to HCV entry could not be
assessed since DTT, at either pH 5 or 7, eliminated detectable
HCVcc infection. The use of selective inhibitors of PDIs, as
opposed to the relatively nonspecific action of DTT, may pro-
vide an alternative method for investigating the possible im-
portance of disulfide bond reorganization in activation of HCV
for productive entry.
Another possibility we explored is proteolytic activation of
the HCV glycoproteins by endosomal proteases. Similar to our
observations for HCV, Ebola virus enters via a pH-dependent
pathway, but these particles cannot fuse at the plasma mem-
brane upon low-pH exposure (18, 42, 47). Infection with VSV
particles pseudotyped with EboV GP is inhibited when the
activities of the CatB and CatL endosomal proteases are
blocked by chemical inhibitors (7). This suggests that EboV
entry requires a proteolytic cleavage, which triggers fusion in
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the endosome. Severe acute respiratory syndrome coronavirus
infection was also shown to be dependent on CatL to cleave its
spike glycoprotein within the endosome (37). Additionally, the
nonenveloped reoviruses require CatB and CatL for efficient
virus disassembly (6, 9). Although inhibitors of CatB/CatL had
no effect on HCV infection, it is still possible that different
endosomal proteases or other endosomal determinants are
required to prime the HCV glycoproteins for fusion.
Alternatively, HCV may be primed for low-pH-induced en-
try by receptor binding or subsequent steps prior to the for-
mation of mature endosomes. Simple binding of HCVcc to
cells at 4°C was not sufficient to activate the virus for low-pH-
induced triggered entry at the plasma membrane. One expla-
nation is that HCV entry at the plasma membrane is nonpro-
ductive for downstream events in the viral life cycle, as
previously observed for Semliki Forest virus and VSV in CHO
cells (28) and avian leukosis virus (29). However, the fact that
low pH could override the bafilomycin block to HCV infection
after incubation at 37°C, shown in Fig. 6, suggests that HCV
can undergo time- and temperature-dependent activation at
the cell surface or in forming endosomes. Although the effects
of the elevated temperature and incubation time warrant fur-
ther study, several scenarios can be envisioned based on pre-
vious work with other enveloped viruses. In the case of avian
leukosis virus and perhaps also for HCV, productive entry
could require not only receptor binding but also a forming
endosome, encountered only after incubation at 37°C (29).
However, even before receptor-mediated endocytosis and for-
mation of mature endosomes, HCV may require interactions
that do not occur during binding at 4°C. For example, HCV
attached to the cell surface via a primary binding determinant
such as CD81 may require interaction with a coreceptor to
stabilize binding and activate the virus for low-pH-induced
entry. This interaction might require lateral diffusion in the
plasma membrane or changes at the plasma membrane that
occur during endosome formation, either of which could be
compromised by low temperature and decreased membrane
fluidity. Future experiments will be aimed at gaining a better
understanding of the steps leading to productive HCV entry,
paying particular attention to interaction between the HCV
glycoproteins and specific molecules, such as CD81, scavenger
receptor BI, low-density lipoprotein receptor, or as-yet-uni-
dentified molecules required for entry.
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